^
Association details:
| Biomarker: | IGF2 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Excerpt:
Five of 21 SD models (23.8%) characterized by particularly high expression of EGFR and EGFR family members regressed after intensified EGFR blockade by cetuximab and a small-molecule inhibitor....interception of IGF2-dependent signaling in IGF2-overexpressing xenopatients potentiated the effects of cetuximab.
DOI:
10.1126/scitranslmed.3010445
